We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $57.67 · 8 analysts
Stored first · Google News · Yahoo Finance (English)
Recon: FDA denies Hengrui-Elevar liver cancer drug for the third time; GSK to pursue FDA nod for Jemperli for rectal cancer - RAPS
Recon: FDA denies Hengrui-Elevar liver cancer drug for the third time; GSK to pursue FDA nod for Jemperli for rectal cancer RAPS
GSK's Jemperli meets main goal in mid-stage rectal cancer trial - Reuters
GSK's Jemperli meets main goal in mid-stage rectal cancer trial Reuters
GSK's New Severe Asthma Med: 'Carry On, With Fewer Attacks' 07/14/2026 - MediaPost
GSK's New Severe Asthma Med: 'Carry On, With Fewer Attacks' 07/14/2026 MediaPost
GSK posts positive interim results for Jemperli in rectal cancer - The Pharma Letter
GSK posts positive interim results for Jemperli in rectal cancer The Pharma Letter
GSK plc (GSK) executives add stock via Share Reward Plan and dividend reinvestment - Stock Titan
GSK plc (GSK) executives add stock via Share Reward Plan and dividend reinvestment Stock Titan
GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win - Fierce Pharma
GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win Fierce Pharma
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 28. | After market close (AMC) | $1.25 | — | — | $8.25B | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 01. 07. | Barclays | — | Downgrade | Equal-Weight → Underweight | — | Barclays: Equal-Weight → Underweight |
| 2024. 11. 12. | Jefferies | — | Downgrade | Buy → Hold | — | Jefferies: Buy → Hold |
| 2024. 11. 01. | Guggenheim | — | Downgrade | Buy → Neutral | — | Guggenheim: Buy → Neutral |
| 2024. 07. 08. | UBS | — | Downgrade | Buy → Neutral | — | UBS: Buy → Neutral |
| 2024. 07. 03. | Jefferies | — | Maintain | Buy → Buy | — | Jefferies: Buy |
| 2024. 05. 30. | Goldman Sachs | — | Initiate coverage | — → Neutral | — | Goldman Sachs: Neutral |
Price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,474,951 | $72.33M | 0.12% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 36,300 | $1.78M | 0.00% | — | New position |